Triple

T22796772
Position Surface form Disambiguated ID Type / Status
Subject CDK6 E564269 entity
Predicate interactsWith P3970 FINISHED
Object cyclin D3
Cyclin D3 is a regulatory protein that controls progression through the G1 phase of the cell cycle by activating cyclin-dependent kinases such as CDK4 and CDK6.
 E1555607 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: cyclin D3 | Statement: [CDK6, interactsWith, cyclin D3]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: cyclin D3
Context triple: [CDK6, interactsWith, cyclin D3]
  • A. cyclin D2
    Cyclin D2 is a regulatory protein that controls progression through the G1 phase of the cell cycle by activating cyclin-dependent kinases involved in cell proliferation.
  • B. CDK4
    CDK4 is a cyclin-dependent kinase that regulates cell cycle progression and is a key therapeutic target in certain cancers.
  • C. CDK6
    CDK6 is a cyclin-dependent kinase that regulates cell cycle progression and is a key target in certain cancer therapies.
  • D. CDKN2D (p19INK4D)
    CDKN2D (p19INK4D) is a cyclin-dependent kinase inhibitor that helps control cell cycle progression by inhibiting CDK4/6 activity and acting as a tumor suppressor.
  • E. CDKN2C (p18INK4C)
    CDKN2C (p18INK4C) is a cyclin-dependent kinase inhibitor that helps control cell cycle progression by inhibiting CDK4/6 activity and acting as a tumor suppressor.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: cyclin D3
Triple: [CDK6, interactsWith, cyclin D3]
Generated description
Cyclin D3 is a regulatory protein that controls progression through the G1 phase of the cell cycle by activating cyclin-dependent kinases such as CDK4 and CDK6.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: cyclin D3
Target entity description: Cyclin D3 is a regulatory protein that controls progression through the G1 phase of the cell cycle by activating cyclin-dependent kinases such as CDK4 and CDK6.
  • A. cyclin D2
    Cyclin D2 is a regulatory protein that controls progression through the G1 phase of the cell cycle by activating cyclin-dependent kinases involved in cell proliferation.
  • B. CDK4
    CDK4 is a cyclin-dependent kinase that regulates cell cycle progression and is a key therapeutic target in certain cancers.
  • C. CDK6
    CDK6 is a cyclin-dependent kinase that regulates cell cycle progression and is a key target in certain cancer therapies.
  • D. CDKN2D (p19INK4D)
    CDKN2D (p19INK4D) is a cyclin-dependent kinase inhibitor that helps control cell cycle progression by inhibiting CDK4/6 activity and acting as a tumor suppressor.
  • E. CDKN2C (p18INK4C)
    CDKN2C (p18INK4C) is a cyclin-dependent kinase inhibitor that helps control cell cycle progression by inhibiting CDK4/6 activity and acting as a tumor suppressor.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2458185f88190b0045227ee420411 completed April 17, 2026, 2:36 p.m.
NER Named-entity recognition batch_69f17cd9b3c0819096050f43a829ec0d completed April 29, 2026, 3:36 a.m.
NED1 Entity disambiguation (via context triple) batch_6a0b9e95a7008190860cf3aac103d07d completed May 18, 2026, 11:19 p.m.
NEDg Description generation batch_6a0ba0f5030c81909efd76deb3e6017d completed May 18, 2026, 11:29 p.m.
NED2 Entity disambiguation (via description) batch_6a0ba1b94c8081909cbd256997af1dca completed May 18, 2026, 11:33 p.m.
Created at: April 17, 2026, 3:30 p.m.